A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
We are a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics. We have ongoing Phase 2 clinical studies for our RNA therapeutic candidates to potentially treat ornithine transcarbamylase (OTC) deficiency and cystic fibrosis (CF). We developed the world’s first approved self-amplifying messenger RNA (sa-mRNA) vaccine, KOSTAIVE® (“KOSTAIVE”), which we have partnered with Seqirus, Inc. (“CSL Seqirus”), a part of CSL Limited. KOSTAIVE has achieved approval in Japan, the European Union and the United Kingdom as a vaccine against COVID-19, and sales of KOSTAIVE began in Japan in October 2024. We have several key platform technologies that we leverage to develop and advance a pipeline of mRNA-based therapeutics for rare genetic disorders with significant unmet medical needs and vaccines for infectious diseases.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 82M | 82M | 152M | 167M | 206M | - |
| Net Income | -66M | -66M | -81M | -30M | 9.3M | -204M |
| EPS | $-2.40 | $-2.40 | $-3.00 | $-1.12 | $0.35 | $-7.74 |
| Free Cash Flow | -75M | -75M | -60M | -21M | 24M | -138M |
| ROIC | -22.2% | -30.7% | -33.6% | -10.7% | 4.0% | -75.8% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.00 | 0.27 | 0.43 | 0.22 | 0.67 | 0.38 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -76M | -76M | -96M | -78M | 12M | -203M |
| Operating Margin | -93.0% | -93.0% | -62.8% | -46.9% | 5.9% | - |
| ROE | -30.7% | -28.9% | -33.6% | -10.7% | 3.5% | -89.2% |
| Shares Outstanding | 27M | 27M | 27M | 27M | 27M | 26M |
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |||
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | 16M | 21M | N/A | N/A | 206M | 167M | 152M | 82M | 82M |
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D | 17M | 34M | 58M | 174M | 148M | 192M | 195M | 112M | 112M |
| SG&A | 21M | 13M | 23M | 41M | 46M | 53M | 53M | 46M | 46M |
| EBIT | -22M | -26M | -72M | -203M | 12M | -78M | -96M | -76M | -76M |
| Op. Margin | -138.5% | -122.7% | N/A | N/A | 5.9% | -46.9% | -62.8% | -93.0% | -93.0% |
| Net Income | -22M | -26M | -72M | -204M | 9.3M | -30M | -81M | -66M | -66M |
| Net Margin | -138.3% | -125.0% | N/A | N/A | 4.5% | -17.8% | -53.1% | -80.2% | -80.2% |
| Non-Recurring | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Returns on Capital | |||||||||
| ROIC | -92.5% | -63.7% | -17.6% | -75.8% | 4.0% | -10.7% | -33.6% | -30.7% | -22.2% |
| ROE | -159.7% | -100.8% | -18.2% | -89.2% | 3.5% | -10.7% | -33.6% | -28.9% | -30.7% |
| ROA | -49.3% | -31.6% | -15.1% | -51.8% | 2.1% | -6.9% | -23.5% | -21.4% | -24.3% |
| Cash Flow | |||||||||
| Op. Cash Flow | -21M | -6.4M | -43M | -135M | 32M | -18M | -60M | -74M | -74M |
| Free Cash Flow | -22M | -7.3M | -45M | -138M | 24M | -21M | -60M | -75M | -75M |
| Owner Earnings | -23M | -9.1M | -51M | -165M | -145K | -56M | -101M | -103M | -103M |
| CapEx | 1.5M | 818K | 1.7M | 3.4M | 7.7M | 2.9M | 648K | 230K | 230K |
| Maint. CapEx | 582K | 684K | 882K | 1.2M | 1.5M | 3.0M | 3.5M | 3.0M | 3.0M |
| Growth CapEx | 896K | 134K | 860K | 2.2M | 6.2M | 0 | 0 | 0 | 0 |
| D&A | 582K | 684K | 882K | 1.2M | 1.5M | 3.0M | 3.5M | 3.0M | 3.0M |
| CapEx/OCF | N/A | N/A | N/A | N/A | 24.1% | N/A | N/A | N/A | 0.0% |
| Capital Allocation | |||||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | 1.3M | 2.0M | 6.8M | 29M | 31M | 35M | 38M | 25M | 25M |
| Debt Repayment | 0 | 0 | 0 | 0 | 5.0M | 47M | 0 | 15M | 15M |
| Balance Sheet | |||||||||
| Net Debt | -64M | -128M | -909M | -655M | -602M | -523M | N/A | N/A | -231M |
| Cash & Equiv. | 37M | 71M | 463M | 370M | 392M | 292M | 237M | 231M | 231M |
| Long-Term Debt | 9.9M | 15M | 14M | 41M | 61M | N/A | N/A | N/A | N/A |
| Debt/Equity | 0.73 | 0.58 | 0.04 | 0.38 | 0.67 | 0.22 | 0.43 | 0.27 | 0.00 |
| Interest Coverage | -149.4 | -36.9 | -95.2 | -296.6 | 15.0 | -2.3 | N/A | N/A | N/A |
| Equity | 14M | 26M | 397M | 228M | 270M | 279M | 241M | 214M | 214M |
| Total Assets | 44M | 82M | 476M | 393M | 450M | 429M | 344M | 271M | 271M |
| Total Liabilities | 31M | 56M | 80M | 165M | 180M | 151M | 103M | 57M | 57M |
| Intangibles | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Retained Earnings | -45M | -72M | -144M | -347M | -338M | -368M | -449M | -515M | -515M |
| Working Capital | 29M | 53M | 418M | 279M | 276M | 305M | 240M | 205M | 205M |
| Current Assets | 42M | 74M | 468M | 379M | 403M | 387M | 306M | 241M | 241M |
| Current Liabilities | 13M | 21M | 50M | 100M | 127M | 82M | 65M | 36M | 36M |
| Per Share Data | |||||||||
| EPS | -2.16 | -2.15 | -3.55 | -7.74 | 0.35 | -1.12 | -3.00 | -2.40 | -2.40 |
| Owner EPS | -2.24 | -0.35 | -2.49 | -6.28 | -0.01 | -2.10 | -3.75 | -3.75 | -3.75 |
| Book Value | 1.35 | 0.98 | 19.51 | 8.67 | 10.12 | 10.49 | 8.93 | 7.81 | 7.81 |
| Cash Flow/Share | -2.06 | -0.25 | -2.11 | -5.13 | 1.20 | -0.68 | -2.21 | -2.71 | -2.29 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 10.1M | 26.3M | 20.3M | 26.3M | 26.7M | 26.5M | 27.0M | 27.4M | 27.4M |
| Valuation | |||||||||
| P/E Ratio | N/A | N/A | N/A | N/A | 46.4 | N/A | N/A | N/A | -3.6 |
| P/FCF | N/A | N/A | N/A | N/A | 17.9 | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | 3.0 | 11.7 | 4.7 | 4.5 | 1.6 | 3.1 | 1.9 | 0.8 | 1.1 |
| Price/Sales | 4.5 | 10.7 | N/A | N/A | 2.6 | 4.0 | 4.7 | 4.6 | 2.9 |
| FCF Yield | -53.6% | -2.4% | -2.4% | -13.5% | 5.6% | -2.4% | -13.2% | -44.1% | -31.3% |
| Market Cap | 41M | 301M | 1.9B | 1.0B | 434M | 875M | 459M | 169M | 238M |
| Avg. Price | 6.98 | 8.43 | 41.13 | 44.88 | 20.12 | 24.83 | 26.47 | 13.73 | 8.68 |
| Year-End Price | 4.11 | 11.46 | 92.42 | 39.10 | 16.24 | 32.97 | 17.02 | 6.16 | 8.68 |
Arcturus Therapeutics Holdings Inc. passes 1 of 9 quality checks, indicating weak fundamentals.
At current prices, the estimated annualized return to fair value is -4.0%.
Arcturus Therapeutics Holdings Inc. (ARCT) has a 5-year average return on invested capital (ROIC) of -29.4%. This is below average and may indicate limited pricing power.
Arcturus Therapeutics Holdings Inc. (ARCT) has a market capitalization of $238M. It is classified as a small-cap stock.
Arcturus Therapeutics Holdings Inc. (ARCT) does not currently pay a regular dividend.
Arcturus Therapeutics Holdings Inc. (ARCT) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
Arcturus Therapeutics Holdings Inc. (ARCT) reported annual revenue of $82 million in its most recent fiscal year, based on SEC EDGAR filings.
Arcturus Therapeutics Holdings Inc. (ARCT) has a net profit margin of -80.2%. The company is currently unprofitable.
Arcturus Therapeutics Holdings Inc. (ARCT) generated $-75 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Arcturus Therapeutics Holdings Inc. (ARCT) has a debt-to-equity ratio of 0.27. This indicates a conservatively financed balance sheet.
Arcturus Therapeutics Holdings Inc. (ARCT) reported earnings per share (EPS) of $-2.40 in its most recent fiscal year.
Arcturus Therapeutics Holdings Inc. (ARCT) has a return on equity (ROE) of -28.9%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 8 years of financial data for Arcturus Therapeutics Holdings Inc. (ARCT), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Arcturus Therapeutics Holdings Inc. (ARCT) has a book value per share of $7.81, based on its most recent annual SEC filing.